Benefits
Raises blood vitamin D faster than vitamin D3
Calcifediol is already the form the liver would make, so blood 25(OH)D climbs within days rather than weeks. A meta-analysis of 17 comparison studies found it outperformed vitamin D3 in 12, matched it in 2 and trailed it in 3. Europe's food safety authority settled on a factor of 2.5 for labelling: each microgram counts as two and a half micrograms of D3.
Supports bone health by correcting low vitamin D status
Vitamin D is needed to absorb calcium and keep bone mineralized, and calcifediol restores the blood marker of vitamin D status efficiently. Direct bone evidence is thin: over four years in adults over 60, 15 mcg a day slowed hip bone loss less than calcium did, only at low calcium intake, and fractures did not differ. In adults over 70 with a prior fall, adding a monthly calcifediol dose to vitamin D3 was followed by more falls, not fewer.
Small microgram doses match larger vitamin D3 doses
Under EFSA's labelling factor of 2.5, 10 mcg of calcifediol, the most allowed per day in supplements for anyone 11 or older, equals 25 mcg (1,000 IU) of vitamin D3. In older adults, 15 to 20 mcg a day brought blood 25(OH)D to 75 nmol/L in 7 to 10 days, against about 40 days on 20 mcg of vitamin D3.
Immune claims rest on vitamin D in general, not this form
Vitamin D contributes to normal immune function, and immune cells activate circulating 25(OH)D on site, so calcifediol supplies exactly what they use. Whether that adds up to fewer infections is unsettled even for ordinary vitamin D3, and the infection evidence for calcifediol itself rests on the two COVID-19 trials described on this page.
Early COVID-19 findings were not confirmed in a blinded trial
An open-label hospital pilot in Spain reported intensive care for 1 of 50 patients given calcifediol versus 13 of 26 without it, but its authors said larger trials with properly matched groups were needed. A later double-blind outpatient trial of an extended-release form, run by its maker, raised blood levels without shortening overall symptom time.
Mechanism of action
Skips the liver's 25-hydroxylation step
Vitamin D3 has to be converted in the liver to 25-hydroxyvitamin D3 before the body can use it. Calcifediol is that product already, so a dose shows up in blood 25(OH)D within days and is not limited by liver 25-hydroxylase activity, which can be impaired in some conditions.
Portal absorption instead of the lymph route
Calcifediol is absorbed almost completely and passes through the portal vein straight into circulation, while vitamin D3 is packaged into chylomicrons and travels through the lymph. This is why reviewers see it as an option after bariatric surgery or with fat malabsorption.
Linear dose response and faster clearance
Blood 25(OH)D rises roughly in a straight line with increasing calcifediol doses, whereas it tends to plateau at high doses of vitamin D3. Calcifediol is also cleared faster once dosing stops, so it corrects status quickly but does not leave a long-lasting reserve.
Final activation stays under hormonal control
The kidney enzyme CYP27B1 converts 25(OH)D into calcitriol, the hormone that raises intestinal calcium absorption and restrains parathyroid hormone. That step stays regulated by the body, so calcifediol acts as a vitamin D source rather than a calcitriol drug, though large excesses can still push calcium up.
Local activation in immune cells
Macrophages and other immune cells carry the same activating enzyme and make calcitriol locally from circulating 25(OH)D. This is the biological basis for vitamin D's role in immune function, and it depends on the blood 25(OH)D level that calcifediol raises directly.
Clinical trials
One-year, double-blind, randomized phase III-IV trial comparing calcifediol 0.266 mg monthly with cholecalciferol 25,000 IU monthly, plus an arm that stopped calcifediol after four months (Pérez-Castrillón JL, Dueñas-Laita A, Gómez-Alonso C, et al. 2023, J Bone Miner Res 38(4):471-479, PMID 36661855). Faes Farma, which sells calcifediol capsules in Spain, holds the paper's copyright and employs three of its authors.
303 postmenopausal women with 25(OH)D below 20 ng/mL randomized; 298 evaluated.
At month 4, mean 25(OH)D was 26.8 ng/mL on continuous calcifediol and 23.1 ng/mL on vitamin D3; by month 12 the gap had narrowed to 23.9 versus 22.4 ng/mL, both still below 30 ng/mL. When calcifediol was stopped after four months, levels fell from 28.5 to 14.4 ng/mL. No relevant treatment-related safety issues were reported. The vitamin D3 comparator worked out to only about 800 IU a day.
Randomized, double-blind, active-comparator trial of daily 25(OH)D3 at 10, 15 or 20 mcg versus vitamin D3 20 mcg for 6 months, followed by 6 months of washout (Graeff-Armas LA, Bendik I, Kunz I, Schoop R, Hull S, Beck M 2020, J Nutr 150(1):73-81, PMID 31518424). Four of the six authors were affiliated with DSM Nutritional Products, the supplement ingredient's maker.
91 adults (53 women, 38 men), mean age 63, with baseline 25(OH)D of about 47 to 50 nmol/L.
Per microgram, 25(OH)D3 was about three times as effective as vitamin D3 at raising blood 25(OH)D. The 15 and 20 mcg groups reached 75 nmol/L in 7 to 10 days, against 40 days on vitamin D3. After dosing stopped, 25(OH)D3 was eliminated 59 to 109 percent faster, so the head start does not persist.
Randomized, double-blind, placebo-controlled trial of 750 mg calcium or 15 mcg 25OH vitamin D3 daily for four years, funded by the US National Institutes of Health (Peacock M, Liu G, Carey M, McClintock R, Ambrosius W, Hui S, Johnston CC 2000, J Clin Endocrinol Metab 85(9):3011-9, PMID 10999778).
438 older volunteers (316 women, mean age 73.7; 122 men, mean age 75.9) with a median baseline 25(OH)D of 59 nmol/L.
On placebo, total hip bone density fell 2% over four years. Calcium reduced that loss, secondary hyperparathyroidism and bone turnover; 25OH vitamin D3 landed between placebo and calcium, and its effect appeared only in people with low calcium intake. Fracture and drop-out rates were similar across groups, with no serious adverse events from either supplement.
Open-label pilot randomized trial allocating patients 2:1 to oral calcifediol (0.532 mg on admission, 0.266 mg on days 3 and 7, then weekly) plus standard care, or standard care alone (Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, Alcalá Díaz JF, López Miranda J, Bouillon R, Quesada Gomez JM 2020, J Steroid Biochem Mol Biol 203:105751, PMID 32871238).
76 patients hospitalized with COVID-19 pneumonia in Córdoba, Spain; standard care at the time included hydroxychloroquine and azithromycin.
One of 50 calcifediol patients needed intensive care, against 13 of 26 controls, and no calcifediol patient died. The trial was small and unblinded, and the authors wrote that larger trials with properly matched groups were required. It generated a hypothesis; it did not settle the question.
Double-blind, placebo-controlled randomized trial of extended-release calcifediol, 300 mcg on days 1 to 3 then 60 mcg on days 4 to 27 (Bishop CW, Ashfaq A, Melnick JZ, et al. 2023, Nutrition 107:111899, PMID 36529089). Four authors were from OPKO Health; the extended-release drug Rayaldee is labeled by OPKO Pharmaceuticals.
171 adults with mild to moderate COVID-19 randomized, 160 treated and 134 retained; mean age 43, mean baseline 25(OH)D about 37 ng/mL.
81% of the calcifediol group reached 25(OH)D of at least 50 ng/mL versus 15% on placebo, but time to resolution of the five aggregated symptoms did not change in the full analysis set (hazard ratio 0.983). A per-protocol subgroup hinted at faster respiratory symptom relief, a secondary finding that needs confirmation. No hypercalcemia was reported.